Eli Lilly and Company (NYSE:LLY) Holdings Decreased by Community Financial Services Group LLC

Community Financial Services Group LLC reduced its position in Eli Lilly and Company (NYSE:LLY) by 2.4% during the 1st quarter, HoldingsChannel.com reports. The firm owned 9,539 shares of the company’s stock after selling 232 shares during the quarter. Eli Lilly and Company makes up about 1.7% of Community Financial Services Group LLC’s investment portfolio, making the stock its 16th largest holding. Community Financial Services Group LLC’s holdings in Eli Lilly and Company were worth $7,878,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Mascagni Wealth Management Inc. acquired a new stake in Eli Lilly and Company in the 4th quarter valued at approximately $43,000. Prudent Man Investment Management Inc. bought a new stake in Eli Lilly and Company during the fourth quarter worth about $48,000. Highline Wealth Partners LLC increased its stake in shares of Eli Lilly and Company by 53.3% in the first quarter. Highline Wealth Partners LLC now owns 69 shares of the company’s stock valued at $57,000 after buying an additional 24 shares in the last quarter. Capital A Wealth Management LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $63,000. Finally, Bellwether Advisors LLC acquired a new stake in Eli Lilly and Company in the fourth quarter worth about $66,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the subject of several analyst reports. Morgan Stanley restated an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Erste Group Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 5th. Guggenheim reaffirmed a “buy” rating and set a $936.00 price objective on shares of Eli Lilly and Company in a research report on Friday, June 20th. Hsbc Global Res cut shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research report on Monday, April 28th. Finally, Wells Fargo & Company reiterated an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,011.61.

Eli Lilly and Company Price Performance

Shares of LLY opened at $778.97 on Wednesday. The business has a 50-day moving average of $781.26 and a 200-day moving average of $800.21. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company has a market capitalization of $738.26 billion, a price-to-earnings ratio of 63.38, a price-to-earnings-growth ratio of 1.13 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). The company had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The company’s revenue for the quarter was up 45.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.58 earnings per share. As a group, equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.77%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company’s dividend payout ratio is currently 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.